Answers are grounded in this paper and cite their sources.
Arsenic, which easily gets bio-magnified, is a potential hazardous metalloid that affects the vital organs of human beings. Considering the limitations and side effects of artificial chelating agents, this study was undertaken to evaluate the ameliorative potential of phenolic extracts of spirulina ( Arthrospira platensis ) in Mus musculus model over haematological and renal degeneration caused by arsenic toxicity. In the fulfillment of the goal, we isolated the phenolic content of spirulina and the total phenolic content was estimated. The phenolic content of spirulina was screened with LC-ESI-MS/MS for the presence of active phenolic content. The phenolic extract of spirulina (100 mg/kg) was used to treat the mice model induced with arsenic toxicity (20 mg/kg). The phenolic content from spirulina showed a significant restoration of blood parameters, viz., haemoglobin (Hb), RBC, WBC, and HCT (p ˂0.05) than arsenic induced group. Decreased weight of kidney and protein concentration, increased kidney marker enzymes, i.e., blood urea nitrogen (BUN), creatinine (p ˂0.05) in blood serum of arsenic induced animal were the indication of reduced renal potential which significantly restored with phenolic content of spirulina co-treatment. Additionally, bioactive phenolic compounds were screened for molecular docking with most abundant proteins in affected organs by using Auto dock 4.6. The main bioactive compounds, viz., 4 Hydroxy coumarin, catechin, myricetin and kaempferol show higher binding potential with actin, albumin, pyruvate dehydrogenase and superoxide dismutase receptor proteins than arsenic trioxide. Hence, these bioactive compounds are capable of replacing arsenic molecules from screened proteins and helps in reduction of arsenic load.
No takes yet. Share an insight, caveat, or question.
Sarkar et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: